Ulcerative Colitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Ulcerative Colitis - Pipeline Review, H2 2016

Ulcerative Colitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Ulcerative Colitis - Pipeline Review, H2 2016
Published Oct 29, 2016
421 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis Pipeline Review, H2 2016, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 14, 28, 20, 1, 1, 45, 12 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively for Ulcerative Colitis.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerativ

  
Source:
Document ID
GMDHC8598IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents220
  List of Tables183
  List of Figures211
Introduction221
  Global Markets Direct Report Coverage221
Ulcerative Colitis Overview231
Therapeutics Development242
  Pipeline Products for Ulcerative Colitis Overview241
  Pipeline Products for Ulcerative Colitis Comparative Analysis251
Ulcerative Colitis Therapeutics under Development by Companies267
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes331
Ulcerative Colitis Pipeline Products Glance344
  Late Stage Products341
  Clinical Stage Products351
  Early Stage Products361
  Unknown Stage Products371
Ulcerative Colitis Products under Development by Companies389
Ulcerative Colitis Products under Investigation by Universities/Institutes471
Ulcerative Colitis Companies Involved in Therapeutics Development4876
  4D Pharma Plc481
  AbbVie Inc491
  Abivax S.A.501
  Advinus Therapeutics Ltd511
  Aerpio Therapeutics, Inc.521
  Am-Pharma B.V.531
  Amgen Inc.541
  Aptevo Therapeutics Inc551
  Arena Pharmaceuticals, Inc.561
  Atlantic Healthcare Plc571
  Bionovis SA581
  Bristol-Myers Squibb Company591
  Celgene Corporation601
  Cellceutix Corporation611
  ChemoCentryx, Inc.621
  ChironWells GmbH631
  Coherus BioSciences, Inc.641
  Cosmo Pharmaceuticals NV651
  Dr. Falk Pharma GmbH661
  EA Pharma Co Ltd671
  Eli Lilly and Company681
  Enceladus Pharmaceuticals BV691
  enGene, Inc701
  Enterome Bioscience SA711
  Epirus Biopharmaceuticals, Inc.721
  Flexion Therapeutics, Inc.731
  Galapagos NV741
  Genentech, Inc.751
  Genor BioPharma Co Ltd761
  GlaxoSmithKline Plc771
  GW Pharmaceuticals Plc781
  iCo Therapeutics Inc.791
  Idera Pharmaceuticals, Inc.801
  InDex Pharmaceuticals AB811
  Innovate Biopharmaceuticals, Inc.821
  INOXIA Lifesciences GmbH831
  Intas Pharmaceuticals Ltd.841
  Johnson &Johnson851
  Kaken Pharmaceutical Co., Ltd.861
  Kyowa Hakko Kirin Co., Ltd.871
  LIPID THERAPEUTICS GmbH881
  Lycera Corp.891
  Medestea Research &Production S.p.A.901
  Merck &Co., Inc.911
  Miyarisan Pharmaceutical Company, Ltd921
  Momenta Pharmaceuticals, Inc.931
  Morphotek, Inc.941
  Mycenax Biotech Inc.951
  NeuClone Pty Ltd961
  Oncobiologics, Inc.971
  OSE Immunotherapeutics981
  Pfizer Inc.991
  Pluristem Therapeutics Inc.1001
  ProtAb Ltd1011
  Protagonist Therapeutics Inc.1021
  Protalix BioTherapeutics, Inc.1031
  Qu Biologics Inc.1041
  Re-Pharm Limited1051
  Rebiotix Inc.1061
  Sandoz International GmbH1071
  Seres Therapeutics, Inc.1081
  Shire Plc1091
  Sigmoid Pharma Limited1101
  Stelic Institute &Co., Inc.1111
  Sterna biologicals Gmbh &Co KG1121
  Synergy Pharmaceuticals, Inc.1131
  Synlogic Inc1141
  Takeda Pharmaceutical Company Limited1151
  Therapeutic Proteins International, LLC1161
  Therapix Biosciences Ltd.1171
  Theravance Biopharma, Inc.1181
  Tillotts Pharma AG1191
  TopiVert Ltd1201
  Trino Therapeutics Limited1211
  UCB S.A.1221
  Ventria Bioscience1231
Ulcerative Colitis Therapeutics Assessment12414
  Assessment by Monotherapy Products1241
  Assessment by Target1254
  Assessment by Mechanism of Action1295
  Assessment by Route of Administration1342
  Assessment by Molecule Type1362
Drug Profiles138256
  ABS-11 Drug Profile1381
  ABX-464 Drug Profile1392
  adalimumab Drug Profile1417
  adalimumab biosimilar Drug Profile1482
  adalimumab biosimilar Drug Profile1501
  adalimumab biosimilar Drug Profile1511
  adalimumab biosimilar Drug Profile1521
  adalimumab biosimilar Drug Profile1531
  adalimumab biosimilar Drug Profile1542
  adalimumab biosimilar Drug Profile1562
  adalimumab biosimilar Drug Profile1581
  adalimumab biosimilar Drug Profile1591
  adalimumab biosimilar Drug Profile1601
  adalimumab biosimilar Drug Profile1611
  AKB-4924 Drug Profile1621
  AKP-11 Drug Profile1632
  alicaforsen sodium Drug Profile1651
  Anatabine Drug Profile1663
  Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer Drug Profile1691
  apremilast Drug Profile17010
  AW/EPO-002 Drug Profile1801
  AW/EPO-003 Drug Profile1811
  AW/EPOPD-01 Drug Profile1821
  AW/EPOPD-02 Drug Profile1831
  AW/EPOPD-06 Drug Profile1841
  bertilimumab Drug Profile1853
  bimekizumab Drug Profile1881
  Biologic for Ulcerative Colitis and Crohn's Disease Drug Profile1891
  BMS-986166 Drug Profile1901
  BMS-986184 Drug Profile1911
  brilacidin tetrahydrochloride Drug Profile1929
  budesonide Drug Profile2013
  carotegrast Drug Profile2042
  CBM-588 Drug Profile2062
  CCX-507 Drug Profile2081
  cobitolimod Drug Profile2094
  cyclosporine CR Drug Profile2131
  D-9030 Drug Profile2141
  DNVX-078 Drug Profile2151
  DNX-514 Drug Profile2161
  dolcanatide Drug Profile2173
  Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis Drug Profile2201
  EB-420 Drug Profile2211
  EFFI-7H Drug Profile2222
  EG-10 Drug Profile2241
  EG-12 Drug Profile2251
  enalaprilat Drug Profile2261
  ES-210 Drug Profile2271
  etanercept biosimilar Drug Profile2282
  etrasimod arginine Drug Profile2302
  etrolizumab Drug Profile2322
  filgotinib Drug Profile23410
  FX-003 Drug Profile2441
  golimumab biosimilar Drug Profile2451
  golimumab biosimilar Drug Profile2461
  golimumab biosimilar Drug Profile2471
  GSK-2982772 Drug Profile2481
  GWP-42003 Drug Profile2492
  hyaluronate sodium Drug Profile2511
  IAC-VITA Drug Profile2522
  IMO-9200 Drug Profile2542
  infliximab Drug Profile2564
  infliximab biosimilar Drug Profile2601
  infliximab biosimilar Drug Profile2611
  infliximab biosimilar Drug Profile2621
  infliximab biosimilar Drug Profile2633
  infliximab biosimilar Drug Profile2661
  infliximab biosimilar Drug Profile2673
  infliximab biosimilar Drug Profile2701
  infliximab biosimilar Drug Profile2711
  INN-108 Drug Profile2721
  INV-88 Drug Profile2731
  KAG-308 Drug Profile2741
  KANAb-071 Drug Profile2752
  KHK-4083 Drug Profile2771
  kPPF-1 Drug Profile2781
  lipidated tacrolimus Drug Profile2791
  LT-0011 Drug Profile2801
  LT-02 Drug Profile2812
  LY-3074828 Drug Profile2831
  LYC-30937 Drug Profile2842
  mesalamine Drug Profile2862
  mesalamine Drug Profile2881
  mesalamine Drug Profile2891
  mesalamine DR Drug Profile2901
  mesalamine ER Drug Profile2912
  mongersen sodium Drug Profile2933
  Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease Drug Profile2961
  naltrexone hydrochloride Drug Profile2973
  NRG-4 Drug Profile3001
  ozanimod hydrochloride Drug Profile3017
  P-Dex Drug Profile3081
  PF-06480605 Drug Profile3091
  PH-44 Drug Profile3101
  PH-46A Drug Profile3111
  PH-5 Drug Profile3121
  PNQ-201 Drug Profile3131
  prednisolone sodium phosphate Drug Profile3142
  Prozumab Drug Profile3161
  PTG-100 Drug Profile3172
  QBECO-SSI Drug Profile3194
  ranibizumab biosimilar Drug Profile3231
  RBX-2660 Drug Profile3243
  RBX-8225 Drug Profile3271
  Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis Drug Profile3283
  Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis Drug Profile3311
  Recombinant Protein for Crohn s Disease and Ulcerative Colitis Drug Profile3321
  RG-7880 Drug Profile3331
  risankizumab Drug Profile3343
  Rosburix Drug Profile3371
  RP-0217 Drug Profile3381
  SB-012 Drug Profile3391
  SER-287 Drug Profile3402
  SER-301 Drug Profile3421
  SHP-647 Drug Profile3432
  Small Molecule to Agonize Mu Opioid Receptor for Crohn's Disease and Ulcerative Colitis Drug Profile3451
  Small Molecule to Agonize S1PR1 for Ulcerative Colitis Drug Profile3461
  Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation Drug Profile3471
  Small Molecules for Crohn s Disease and Ulcerative Colitis Drug Profile3481
  Small Molecules for Crohns Disease and Ulcerative Colitis Drug Profile3491
  Small Molecules for Rheumatoid Arthritis and Ulcerative Colitis Drug Profile3501
  Small Molecules to Antagonize CCR9 for Crohn's Disease and Ulcerative Colitis Drug Profile3511
  Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Crohn's Disease and Ulcerative Colitis Drug Profile3521
  Small Molecules to Inhibit IL-13 for Ulcerative Colitis Drug Profile3531
  sodium hypochlorite Drug Profile3541
  Stem Cell Therapy for Inflammatory Bowel Disease Drug Profile3552
  STNM-01 Drug Profile3571
  TD-1473 Drug Profile3582
  TD-3504 Drug Profile3601
  tofacitinib citrate Drug Profile36111
  TOP-1210 Drug Profile3721
  TOP-1288 Drug Profile3732
  TP-10 Drug Profile3751
  TRX-318 Drug Profile3762
  upadacitinib tartrate Drug Profile3782
  ustekinumab Drug Profile3806
  VEDA-1209 Drug Profile3861
  vedolizumab Drug Profile3876
  VEN-120 Drug Profile3931
Ulcerative Colitis Dormant Projects39410
Ulcerative Colitis Discontinued Products4042
Ulcerative Colitis Product Development Milestones40614
  Featured News &Press Releases4061
    Oct 18, 2016: Results from InDex Pharmaceuticals COLLECT study well received at UEGW4061
    Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG4071
    Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn s Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting4082
    Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies4101
    Oct 15, 2016: Pfizer to Present New Data on XELJANZ (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 20164111

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Ulcerative Colitis - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ulcerative-Colitis-Pipeline-Review-H2-2016-2088-16714>
  
APA:
Global Markets Direct - Market Research. (2016). Ulcerative Colitis - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ulcerative-Colitis-Pipeline-Review-H2-2016-2088-16714>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.